Abstract:Patients with rheumatoid arthritis (RA) have a two to five times increased risk of developing premature cardiovascular disease that shortens life expectancy by 5-10 years. Traditional risk factors known to promote and accelerate the progression of atherosclerotic lesions however, are often absent in patients with RA. Many similarities have emerged between the paradigm of inflammation in the pathogenesis of atherosclerosis and the well-established mechanisms of inflammation in the pathogenesis of RA. Hence it is intriguing to speculate that inflammation in RA is not confined to the joints but also present in the vessel wall. Indeed, low-grade inflammation and endothelial dysfunction play pivotal roles in the initiation, progression and propagation of the atherosclerotic process. While the healthy endothelium prevents adhesion of mononuclear cells, the defence mechanisms cease under the influence of cardiovascular risk factors and inflammation and they express adhesion molecules (selectins, vascular adhesion molecule-([VCAM-]1, intercellular adhesion molecule-[ICAM-]1) that promote the adherence of monocytes. This expression is induced by pro-inflammatory cytokines such as interleukin-(IL-)1beta and tumor necrosis factor-(TNF-)alpha, by C-reactive protein (CRP), and CD40/CD40 ligand interactions. As all of these factors are present at increased levels in the systemic circulation in RA, it appears possible that they might impact the endothelium as well. Further similarities include proteolytic enzymes such as matrix metalloproteinases (MMPs) that play a role in joint destruction as well as in destabilization and rupture of vulnerable atherosclerotic plaques. In addition, coagulation factors such as increased levels of tissue factor (TF), van Willebrand factor (vWF) and plasminogen activator inhibitor-(PAI-)1 are important in both, RA and CAD. Endothelial dysfunction has shown to correlate with cardiovascular prognosis in several studies, which indicates its clinical relevance. Endothelial function measurement is performed in the coronary or peripheral circulation (by venous occlusion plethysmography or flow-mediated dilation). Recent studies have demonstrated impaired endothelial function in patients with RA, already at early stages of the disease. Similar results are found in patients with systemic lupus erythematosus (SLE), indicating that inflammation per se may impair altering vascular function. This and more evidence supports the notion that inflammation plays a pivotal role in vascular dysfunction and may by these mechanisms explain at least part of the excess morbidity and mortality observed in RA and SLE. In light of the growing evidence of increased cardiovascular morbidity and mortality mostly independent of traditional risk factors, treatment strategies in RA should not only aim at relieving symptoms and inhibiting joint destruction but should have a beneficial effect on the vasculature to reduce cardiovascular events. Indeed, an improvement in endothelial function in RA was recently demonstrated by anti-TNF-alpha therapy and statins. Whether and to what degree the effects of anti-inflammatory strategies to improve endothelial function, which although clinically well established is still a surrogate, translate into clinical benefit for our patients with rheumatologic diseases needs to be determined in large-scale clinical trials some of which are now already under way.

Contribution of selected serum inflammatory mediators to the progression of chronic rheumatic valve disease, subsequent valve calcification and NYHA functional class.

Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease.

Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification

New insight into the role of lipid metabolism-related proteins in rheumatic heart valve disease

Aortic valve calcification is promoted by interleukin-8 and restricted through antagonizing CXCR2.

Antibody Microarray Analysis of Serum Inflammatory Cytokines in Patients with Calcific Aortic Valve Disease

Synergistic Effects of Cyclic Strain and Th1-like Cytokines on Tenascin-C Production by Rheumatic Aortic Valve Interstitial Cells

Aortic valve calcification is promoted by interleukin-8 and restricted through antagonizing CXC motif chemokine receptor 2

[Rheumatoid arthritis, inflammation, and atherosclerosis]

Uncoupling the Vicious Cycle of Mechanical Stress and Inflammation in Calcific Aortic Valve Disease

IL-6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction

Exploring the regulation of circulating factors involved in aortic valve sclerosis onset

Study on the Relationship Between Inflammatory Markers of the Patients with Rheumatic Mitral Valve Disease in the Peripheral Blood

Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

Autoimmune Response Confers Decreased Cardiac Function in Patients with Rheumatic Mitral Lesion Following Valve Replacement

Correlation of Serum Inflammatory Cytokines Levels with Cardiac Function in Elderly Patients with Heart Failure

Interleukin 6 plasma levels are associated with progression of coronary plaques

Interleukin-6 positively correlates with cardiovascular disease predictor algorithms and biomarker in rheumatoid arthritis patients

Changes and clinical significance of serum inflammatory factors in patients with rheumatoid arthritis at different stages

Enhanced Association of Novel Cardiovascular Biomarkers Fetuin-A and Catestatin with Serological and Inflammatory Markers in Rheumatoid Arthritis Patients

CD4+ T Cells and TGFβ1/MAPK Signal Pathway Involved in the Valvular Hyperblastosis and Fibrosis in Patients with Rheumatic Heart Disease.